Spontaneous Regression of Hepatic Diffuse Large B-cell Lymphoma in HIV and HCV Positive Patient: A Novel Case Study

Albert Alhatem1*, Saiaditya Badeti1, Chen Liu1,2,3,4, Dongfang Liu1,2,3 and Donghong Cai1,5

1Department of Pathology, Immunology and Laboratory Medicine, Rutgers University, New Jersey Medical School, Newark, NJ, USA
2Department of Medicine, Rutgers New Jersey Medical School, Newark, NJ, USA
3Rutgers Cancer Institute of New Jersey, Newark, NJ, USA
4Department of Pathology, Immunology and Laboratory Medicine, Robert Wood Johnson, New Brunswick, NJ, USA
5Department of Pathology and Laboratory Medicine, Veterans Affairs New Jersey Health Care System, East Orange, NJ, USA

*Corresponding author: Albert Alhatem, MD, Department of Pathology, Immunology and Laboratory Medicine Rutgers New Jersey Medical School, 150 Bergen St, Room E163A, Newark, NJ 0713, USA

Abstract
Objective/Background: Diffuse large B-cell lymphoma (DLBCL) rarely occurs in the liver. Spontaneous regression of this tumor is extremely rare. We are reporting the first case of hepatic DLBCL, and we are reviewing the English literature for cases of spontaneous regression of DLBCL and cancer in general.

Methods: A 60-year-old gentleman with a history of HIV and HCV infections presented with an incidental liver mass. He was diagnosed with DLBCL germinal cell type with high grade features based on the results of pathological/cytogenetics studies. He started HCV and HIV medication but refused lymphoma chemotherapy.

Results: Radiological follow up during a four-year period showed a spontaneous regression of his liver mass to a non-detectable size. Review of the English literature revealed 18 cases of DLBCL spontaneous regression, none of which were found in the liver. Here, two mechanisms are proposed to explain this phenomenon; the immunologic and the genetic.

Conclusion: Chemoimmunotherapy is recommended for all DLBCL patients. However, this case of DLBCL spontaneous regression in an HIV and HCV positive patient offers a rare platform to understand the immune and genetic mechanisms for cancer and lymphoma in particular.

Keywords
Diffuse large B-cell lymphoma, Spontaneous cancer regression, Tumor associated antigens, Human Immune Deficiency Virus

Introduction
The miraculous self-healing of cancer without treatment has fascinated the medical and non-medical community for ages. There are a few case studies in the literature documenting spontaneous regression of malignant tumors [1]. Though these studies offered some explanations for this phenomenon, the mechanisms are still elusive. Therefore, understanding the nature of spontaneous remission in cancer would not only satisfy the curiosity of the mind but could also provide a potential platform to treat cancer patients.

The first reported case of spontaneous cancer regression was in the 14th century [2]. Peregrine Laziosi (1265-1345) was a priest and later became the patron saint of cancer patients. It was reported that he had his bone sarcoma spontaneously healed by divine intervention after a severe bacterial infection [2,3]. In late 1800, William Coley noted that inducing a fever could result
in tumor regression, which led him to later develop a bacterial vaccine (“Coley’s vaccine”) that was successful in reducing tumors in some of his patients [4]. Later in 1956, Everson and Cole, et al. defined the modern version of spontaneous regression of cancer as: “the partial or complete disappearance of a malignant tumor in the absence of all treatment, or in the presence of therapy, which is considered inadequate to exert a significant influence on neoplastic disease [5-7]”. 

There are a few reports of biopsy-confirmed malignancies that later spontaneously regressed, which include garden variety cancer types and histology. Examples include: Acute myelocytic leukemia, chronic lymphocytic leukemia, Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, breast cancer, non-small cell and small cell lung cancer, testicular cancer, prostate cancer, cervical cancer, hepatocellular cancer, colon cancer, Merkel cell carcinoma, sarcoma, melanoma, neuroblastoma, astrocytoma, and renal cell carcinoma [8-25]. The frequency of this phenomenon in all cancers has been reported as 1 case per 80,000-100,000 [25]. While not uncommon in low-grade lymphomas, spontaneous remission in aggressive, high-grade NHL is rare [25].

We present here for the first time a case of a spontaneous remission of liver diffuse large B-cell lymphoma. We also reviewed the literature to seek some explanations for this interesting phenomenon.

**Case Presentation**

A 60-year-old male with history of hepatitis C virus (2003) and human immunodeficiency virus (2009) infections presented with an incidental liver mass on ultrasonography in 2014. Triple-phase computed tomography (CT) study confirmed a 6 × 5.3 × 3 cm heterogeneous-ly enhancing mass in the right hepatic lobe (Figure 1a and Figure 1b). Borderline enlarged lymph nodes were noted in the base of the right heart and in the right paraoesophageal and IVC junction region, the largest of which measured 1.2 × 1.3 cm.

CT-guided Liver core biopsy showed diffuse infiltration of large atypical lymphocytes (Figure 2a). Immunohistochemistry showed that the atypical lymphocytes

---

**Figure 1:** a,b) Computer Tomography images showing the liver mass obtained in 2014 showing the liver mass at the time of diagnosis.

**Figure 2:** A summary panel of the histopathologic examination of the mass. Hematoxylin and Eosin stain a) Showing large malignant cells with scattered small lymphocytes in the background; b) Immunohistochemical stains for CD20; c) Ki-67; b) Bcl-6 were positive in the malignant cells, CD10 and MUM-1 were negative (not shown), all consistent with diffuse large B-cell lymphoma, germinal center B-cell subtype.
were positive for CD20 and Bcl-6 (Figure 2b and Figure 2d). They were negative for Bcl-2, MUM-1, CD10, CD30, Cyclin D1, and EBER. CD3, CD5 highlighted a few scattered T-cells and CD21 revealed no dendritic cell meshwork. Ki-67 proliferative index was more than 90% (Figure 2c). Florescence In-Situ Hybridization study revealed no BCL2, BCL6, or c-MYC gene rearrangement. The findings were consistent with a DLBCL, germinal center B-cell type, with high grade features. Bone marrow biopsy showed normocellular marrow for age with no evidence of involvement by B-cell lymphoma.

The patient was started on HCV medications and Highly Active Antiretroviral Therapy (HAART) but refused chemotherapy for lymphoma. In 2017, CT showed a poorly heterogenous right peripheral lesion measured 2.6 cm compared to 6 cm in greatest dimension in the previous study (2014). There was no evidence of lymphadenopathy. In 2018, CT revealed that the previous liver lesion regressed to 0.9 cm (Figure 3a, and Figure 3b) and disappeared completely in 2019. During all this time period (2014-2019), the patient received no oncological therapy. On his follow up visit his HCV and HIV levels were undetectable.

Discussion

Spontaneous regression of cancer is rare. For lymphoma cases, one study reported 2 out of 69 diffuse large B-cell lymphoma cases (2.9%) and 18 out of 140 follicular lymphoma cases (12.9%) underwent spontaneous remission, including cases with relapsed or stable disease after treatment [26]. Another report found 6 out of 44 cases of low grade lymphomas (13.6%) without previous treatment showed spontaneous remission [27]. There are some reports in the literature trying to provide explanations for this fascinating phenomenon [28,29], yet the mechanism for which is still largely not well understood. Two mechanisms have been proposed in the literature: The systemic immune response and the genetic mechanism.

Immune response mechanism

One likely reason for spontaneous regression is that an antitumor immune response from the patient is triggered by either specific antigens expressed on the tumor associated antigens (TAAs), infection, or injury. This field of study was initiated by the work of Lloyd Old, the founder of modern cancer immunology. He observed the phenomenon in studying melanoma histopathology. In regression cases, high numbers of immune cells were often found inside the melanocytic tumor nests. He assumed the tumor cells expressed unique antigens that stimulated the host immune system. He also observed that in one renal cell carcinoma patient with pulmonary metastasis that surgical removal of a part of the tumor resulted in spontaneous regression of the remaining tumor [30]. Again he assumed that the surgery (and the subsequent inflammation) stimulated/triggered the host immune response and eliminated the rest of the tumor cells. Spontaneous remission has also been frequently observed in patients with concomitant viral infections, such as human immunodeficiency virus and Epstein-Barr virus [31,32]. Interestingly, our patient has HIV and HCV infection, which could serve as a plausible mechanism for regression. The potential mechanisms behind immunologic stimuli inducing remission are many, but a unifying theory involves the immune system gaining the ability to recognize and react to malignant cells which were otherwise able to evade recognition previously. Therefore, any impetus that activates host immunity theoretically enhances the possibility of host recognition of malignant cells.

The immune-editing theory as proposed by Schreiber, Smyth and Old, et al. [33] has refined the understanding of spontaneous regression by positing a process by which cancer cells alter their immunological profile leading to incomplete elimination, equilibrium, and immune escape [30]. Under ideal conditions, the innate and adaptive immunity work in harmony to destroy cancer cells but often imperfectly, thus explaining why
most spontaneously regressed cancers recur, sometimes even years later. The abscopal (or out-of-field) effect of radiation therapy is another example that supports this observation. It is theorized that the release of tumor associated antigens following radiotherapy causes the immune system to mount a systemic response to distant metastases [34].

Due to its rapid progression, diffuse large B-cell lymphoma (DLBCL), is often deadly without immediate immunochemotherapy [35]. A reduced number of chemotherapy cycles with a local radiation therapy is recommended for patients with localized disease [36]. However, the specific location of the lymphoma and nodal or extranodal status have been proposed as factors for determining the mechanism by which the tumor is regressed. The microenvironment is different between nodal and extranodal tumors. However, this assumption is based on limited information available in the literature as only one nodal case of DLBCL has been reported to have spontaneously regressed compared to the 17 reported extranodal cases of DLBCL [29], with the most common locations being the head and neck [31,37-41], breast [32,42,43], and stomach [44-46]. Other locations include the lumbar spine [47], chest wall [48], and skin [49]. Therefore, it is important to further investigate this concept to shed more light on this area [50]. Furthermore, the physical disruption of the tumor microenvironment has been proposed as the mechanism by which DLBCL regressed as every reported case regressed following a surgical biopsy similar to the renal cell carcinoma case, which is believed to stimulate the immune system to cancer antigens.

Other pieces of evidence that support the immune response mechanism are the presence of fibrosis and small lymphocytes infiltrating the tissue of regressed lymphoma cases [51], the cross-reactivity of pathogen-specific T-cells with tumor antigens [52,53], and nonspecific tumor killing due to natural killer cell activation in response to a viral or bacterial infection [26,27].

Genetic mechanism

Human genetics are vastly varied, and can influence a tumor’s behavior. This could explain why some cancers are aggressive in some people, but spontaneously regress in others. Mutations in some cancers can affect the tumor growth, metastasis, and response to treatment. As such, genetic mutations have been proposed as a mechanism for spontaneous regression. For example, the presence of tropomyosin receptor kinase A (TrkA) cell receptors, hyperdiploidy, and telomerase control dictates whether neuroblastoma regresses spontaneously in children under 18 months (type 1) or displays an aggressive phenotype (type 2) with a 40-50% survival rate in children older than 18 months [54]. Moreover, epigenetic changes can modify the activity of various proteins by changing the behavior of different DNA regions, which leads to the apoptosis of the cancer cells in neuroblastoma [55,56]. More research remains to be seen in this area, which could be invaluable in developing new cancer treatment strategies.

Conclusions

In summary, we presented here for the first time a case of spontaneous remission of DLBCL in the liver. Because it is a rare phenomenon with few documented cases, the mechanism by which this remission occurred is not well understood. Though it is obviously recommended to provide all DLBCL patients with chemoimmunotherapy as soon as they are diagnosed, having rare cases with spontaneous tumor regression may shed light on the pathogenesis and treatment of lymphoma and cancer in general. In our patient, having concomitant viral infections (HIV and HCV), could be categorized as an immune system gain of function to recognize and react to malignant cells as previously described in Ogawa, et al. [44] and Machida, et al. [48] Understanding the immune and genetic mechanisms of these spontaneous remissions could lead to the establishment of new animal models, and the development of new therapeutic strategies for the treatment of cancer.

Acknowledgment

None.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

References


